Scientific News
FA Cardiology Research Abstracts
Myocardial ischemia in the absence of epicardial coronary artery disease in Friedreich's ataxia.
Raman SV, Dickerson JA, Al-Dahhak R. J Cardiovasc Magn Reson. 2008 Apr 8;10(1):15.
Proteomic analysis of hearts from frataxin knockout mice: marked rearrangement of energy metabolism, a response to cellular stress and altered expression of proteins involved in cell structure, motility and metabolism.
Sutak R, Xu X, Whitnall M, Kashem MA, Vyoral D, Richardson DR. Proteomics. 2008 Apr;8(8):1731-41
The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues.
Al-Mahdawi S, Pinto RM, Ismail O, Varshney D, Lymperi S, Sandi C, Trabzuni D, Pook M. Hum Mol Genet. 2008 Mar 1;17(5):735-46. Epub 2007 Nov 27.
Friedreich's ataxia as a cause of premature coronary artery disease.
Giugliano GR, Sethi PS. Tex Heart Inst J. 2007;34(2):214-7.
Cardiomyopathy in Friedreich's ataxia-assessment by cardiac MRI.
Meyer C, Schmid G, Görlitz S, Ernst M, Wilkens C, Wilhelms I, Kraus PH, Bauer P, Tomiuk J, Przuntek H, Mügge A, Schöls L. Mov Disord. 2007 Aug 15;22(11):1615-22.
Myocardial blood flow and oxygen consumption in patients with Friedreich's ataxia prior to the onset of cardiomyopathy.
Gregory SA, MacRae CA, Aziz K, Sims KB, Schmahmann JD, Kardan A, Morss AM, Ellinor PT, Tawakol A, Fischman AJ, Gewirtz H. Coron Artery Dis. 2007 Feb;18(1):15-22
Iron and iron-responsive proteins in the cardiomyopathy of Friedreich's ataxia.
Michael S, Petrocine SV, Qian J, Lamarche JB, Knutson MD, Garrick MD, Koeppen AH. Cerebellum. 2006;5(4):257-67.
Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.
Hart PE, Lodi R, Rajagopalan B, Bradley JL, Crilley JG, Turner C, Blamire AM, Manners D, Styles P, Schapira AH, Cooper JM. Arch Neurol. 2005 Apr;62(4):621-6.
Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
Seznec H, Simon D, Monassier L, Criqui-Filipe P, Gansmuller A, Rustin P, Koenig M, Puccio H. Hum Mol Genet. 2004 May 15;13(10):1017-24. Epub 2004 Mar 17.
Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial.
Rustin P, Bonnet D, Rötig A, Munnich A, Sidi D Neurology. 2004 Feb 10;62(3):524-5; author reply 525; discussion 525.
Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial.
Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S. Neurology. 2003 May 27;60(10):1676-9.
The use of antioxidants in Friedreich's ataxia treatment.
Rustin P. Expert Opin Investig Drugs. 2003 Apr;12(4):569-75.
Cardiac energetics correlates to myocardial hypertrophy in Friedreich's ataxia.
Bunse M, Bit-Avragim N, Riefflin A, Perrot A, Schmidt O, Kreuz FR, Dietz R, Jung WI, Osterziel KJ. Ann Neurol. 2003 Jan;53(1):121-3.
Cardiac bioenergetics in Friedreich's ataxia.
Lodi R, Rajagopalan B, Schapira AH, Cooper JM. Ann Neurol. 2003 Oct;54(4):552; author reply 552-3.
Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia.
Rustin P, Rötig A, Munnich A, Sidi D. Free Radic Res. 2002 Apr;36(4):467-9.
The varying evolution of Friedreich's ataxia cardiomyopathy.
Casazza F, Morpurgo M.; Am J Cardiol 1996 Apr 15;77 (10): 895-8.
Progression of cardiopathology in Friedreich ataxia.
Casazza F, Ferrari F, Piccone U, Maggiolini S, Capozi A, Morpurgo M. Cardiologia. 1990 May;35(5):423-31. Italian.
Progression of hypertrophic into a dilated left ventricle in Friedreich's ataxia.
Casazza F, Morpurgo M. G Ital Cardiol. 1988 Jul;18(7):615-8.